Sino Biopharmaceutical Limited (FRA:SMZ1)

Germany flag Germany · Delayed Price · Currency is EUR
0.7352
-0.0142 (-1.89%)
At close: Jul 18, 2025, 10:00 PM CET
117.58%
Market Cap13.49B
Revenue (ttm)3.82B
Net Income (ttm)463.14M
Shares Outn/a
EPS (ttm)0.03
PE Ratio29.13
Forward PE34.08
Dividend0.00 (0.67%)
Ex-Dividend DateJun 16, 2025
Volume9,750
Average Volume11,804
Open0.7352
Previous Close0.7494
Day's Range0.7352 - 0.7352
52-Week Range0.3179 - 0.7494
Betan/a
RSI75.09
Earnings DateAug 25, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]

Industry Pharmaceutical Preparations
Founded 2000
Employees 24,379
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SMZ1
Full Company Profile

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.